Cencora Management
Management criteria checks 2/4
Cencora's CEO is Bob Mauch, appointed in Oct 2022, has a tenure of 2.17 years. total yearly compensation is $7.70M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.027% of the company’s shares, worth $12.14M. The average tenure of the management team and the board of directors is 1.2 years and 7.1 years respectively.
Key information
Bob Mauch
Chief executive officer
US$7.7m
Total compensation
| CEO salary percentage | 12.7% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.2yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Cencora's (NYSE:COR) Soft Earnings Are Actually Better Than They Appear
Dec 05
Cencora (NYSE:COR) Is Increasing Its Dividend To $0.55
Nov 09Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price
Oct 31Here's Why We Think Cencora (NYSE:COR) Is Well Worth Watching
Oct 10Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Sep 18Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating
Sep 18Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings
Jul 16Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning
Jun 30Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?
Jun 28Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Jun 09Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?
May 21Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings
Apr 05Cencora Remains Chronically Undervalued, With Material Growth Potential
Mar 25Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 18Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly
Feb 25Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 07Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price
Jan 05Cencora: Continued Economic Value On The Table Across All Investment Horizons
Jan 04Cencora: New Name, Same Old Economic Leverage, Reiterate Buy
Oct 18AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)
Jul 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | n/a | n/a | US$2b |
| Sep 30 2023 | US$8m | US$975k | US$2b |
| Jun 30 2023 | n/a | n/a | US$2b |
| Mar 31 2023 | n/a | n/a | US$2b |
| Dec 31 2022 | n/a | n/a | US$2b |
| Sep 30 2022 | US$6m | US$850k | US$2b |
| Jun 30 2022 | n/a | n/a | US$2b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | n/a | n/a | US$2b |
| Sep 30 2021 | US$6m | US$800k | US$2b |
| Jun 30 2021 | n/a | n/a | -US$4b |
| Mar 31 2021 | n/a | n/a | -US$4b |
| Dec 31 2020 | n/a | n/a | -US$3b |
| Sep 30 2020 | US$4m | US$700k | -US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | n/a | n/a | US$649m |
| Sep 30 2019 | US$4m | US$675k | US$855m |
| Jun 30 2019 | n/a | n/a | US$956m |
| Mar 31 2019 | n/a | n/a | US$930m |
| Dec 31 2018 | n/a | n/a | US$1b |
| Sep 30 2018 | US$3m | US$675k | US$2b |
Compensation vs Market: Bob's total compensation ($USD7.70M) is below average for companies of similar size in the US market ($USD12.67M).
Compensation vs Earnings: Bob's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Bob Mauch (57 yo)
2.2yrs
Tenure
US$7,697,850
Compensation
Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.6yrs | US$17.51m | 0.17% $ 74.0m | |
| President | 2.2yrs | US$7.70m | 0.027% $ 12.1m | |
| Executive VP & CFO | 6.1yrs | US$5.45m | 0.077% $ 34.3m | |
| Executive VP & Chief Legal Officer | 3.3yrs | US$4.03m | 0.0097% $ 4.3m | |
| Senior VP | 12.9yrs | no data | 0.011% $ 5.1m | |
| Executive VP | less than a year | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | 5.9yrs | US$3.48m | 0.011% $ 5.1m | |
| EVP & President of U.S. Pharmaceuticals | less than a year | no data | no data | |
| EVP & President of International Business Group | less than a year | no data | no data | |
| Executive VP and Chief Strategy and M&A Officer | less than a year | no data | no data |
1.2yrs
Average Tenure
57yo
Average Age
Experienced Management: COR's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.6yrs | US$17.51m | 0.17% $ 74.0m | |
| President | less than a year | US$7.70m | 0.027% $ 12.1m | |
| Independent Director | 1.2yrs | no data | no data | |
| Independent Director | 16.3yrs | US$300.10k | 0.012% $ 5.2m | |
| Lead Independent Director | 9.3yrs | US$380.05k | 0.010% $ 4.5m | |
| Independent Director | 11.6yrs | US$332.60k | 0.0058% $ 2.6m | |
| Independent Director | 14.6yrs | US$320.10k | 0.011% $ 4.8m | |
| Independent Director | 4.9yrs | US$375.36k | 0.0053% $ 2.3m | |
| Director | 9.9yrs | no data | no data | |
| Independent Director | 1.2yrs | no data | no data | |
| Independent director | 2.2yrs | US$397.33k | 0.000090% $ 40.0k | |
| Independent Director | 1.9yrs | US$311.82k | 0.00081% $ 359.8k |
7.1yrs
Average Tenure
63yo
Average Age
Experienced Board: COR's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 23:51 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |